H Schefer

466 total citations
14 papers, 336 citations indexed

About

H Schefer is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, H Schefer has authored 14 papers receiving a total of 336 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 4 papers in Surgery and 3 papers in Molecular Biology. Recurrent topics in H Schefer's work include Testicular diseases and treatments (3 papers), Cancer Treatment and Pharmacology (2 papers) and Hair Growth and Disorders (1 paper). H Schefer is often cited by papers focused on Testicular diseases and treatments (3 papers), Cancer Treatment and Pharmacology (2 papers) and Hair Growth and Disorders (1 paper). H Schefer collaborates with scholars based in Switzerland, Chile and Germany. H Schefer's co-authors include Martin F. Fey, Daniel Betticher, R Joss, Michele Ghielmini, Francesco Bertoni, Rolf A. Stahel, Mario Bargetzi, Shu‐Fang Hsu Schmitz, Nicolas Ketterer and Gabriella Pichert and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and Annals of Oncology.

In The Last Decade

H Schefer

9 papers receiving 318 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
H Schefer Switzerland 6 163 141 88 78 57 14 336
Marin Nola Croatia 11 129 0.8× 120 0.9× 39 0.4× 66 0.8× 40 0.7× 31 405
J. K. C. Chan China 8 134 0.8× 105 0.7× 26 0.3× 79 1.0× 29 0.5× 15 328
E.‐W. Schwarze Germany 13 284 1.7× 124 0.9× 112 1.3× 36 0.5× 60 1.1× 37 470
Jai Hyang Go South Korea 8 189 1.2× 125 0.9× 51 0.6× 67 0.9× 16 0.3× 29 288
Jung Dal Lee South Korea 7 250 1.5× 190 1.3× 56 0.6× 108 1.4× 33 0.6× 19 351
Priti Trivedi India 10 96 0.6× 74 0.5× 68 0.8× 107 1.4× 106 1.9× 79 340
Lindsey Schneider United States 9 119 0.7× 74 0.5× 155 1.8× 119 1.5× 138 2.4× 18 522
Ramona Mayer Austria 11 49 0.3× 63 0.4× 29 0.3× 54 0.7× 114 2.0× 16 324
Neel Hammond United States 7 146 0.9× 106 0.8× 97 1.1× 126 1.6× 156 2.7× 11 422
Subhash C. Gulati United States 7 155 1.0× 134 1.0× 100 1.1× 99 1.3× 89 1.6× 12 380

Countries citing papers authored by H Schefer

Since Specialization
Citations

This map shows the geographic impact of H Schefer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H Schefer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H Schefer more than expected).

Fields of papers citing papers by H Schefer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H Schefer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H Schefer. The network helps show where H Schefer may publish in the future.

Co-authorship network of co-authors of H Schefer

This figure shows the co-authorship network connecting the top 25 collaborators of H Schefer. A scholar is included among the top collaborators of H Schefer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H Schefer. H Schefer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Pfister, Stefan M., et al.. (2024). Case report: Secondary failure to tolvaptan in a patient with SCLC and paraneoplastic SIADH. Frontiers in Endocrinology. 15. 1382066–1382066. 1 indexed citations
2.
Betticher, Daniel, Geoffrey Delmore, Sandro Anchisi, et al.. (2013). Efficacy and tolerability of two scalp cooling systems for the prevention of alopecia associated with docetaxel treatment. Supportive Care in Cancer. 21(9). 2565–2573. 51 indexed citations
3.
Gautschi, Oliver, et al.. (2013). Experience in Integrating <i>ALK</i> Testing and Crizotinib into the Routine Treatment of Patients with Non-Small Cell Lung Cancer. Oncology Research and Treatment. 36(6). 342–347. 3 indexed citations
4.
Himmelmann, Andreas & H Schefer. (2009). Microangiopathic haemolytic anaemia in a patient with metastatic breast cancer. British Journal of Haematology. 146(3). 231–231. 4 indexed citations
6.
Westermann, Patrick, H Schefer, Markus Borner, & Urs E. Studer. (2007). 535 LONG-TERM FOLLOW-UP RESULTS AFTER ONE CYCLE OF BEP CHEMOTHERAPY IN PATIENTS WITH HIGH RISK CLINICAL STAGE I NONSEMINOMATOUS GERM CELL TESTICULAR TUMOR. European Urology Supplements. 6(2). 156–156.
7.
Ghielmini, Michele, Shu‐Fang Hsu Schmitz, Sergio Cogliatti, et al.. (2004). Effect of Single-Agent Rituximab Given at the Standard Schedule or As Prolonged Treatment in Patients With Mantle Cell Lymphoma: A Study of the Swiss Group for Clinical Cancer Research (SAKK). Journal of Clinical Oncology. 23(4). 705–711. 154 indexed citations
8.
Schefer, H, et al.. (1998). Hereditary persistence of α-fetoprotein. Annals of Oncology. 9(6). 667–672. 39 indexed citations
9.
Joss, R, et al.. (1998). [Current aspects and problems relating to medical ethics in oncology].. PubMed. 87(1-2). 26–32. 1 indexed citations
10.
Aeschlimann, C., A Küpfer, H Schefer, & T. Cerny. (1998). Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy.. PubMed. 26(9). 883–90. 29 indexed citations
11.
Schefer, H, et al.. (1997). [Emergencies in oncology].. PubMed. 86(8). 296–301.
12.
Aeschbacher, Beat C., et al.. (1995). [Cardioprotection in chemo- and radiotherapy for malignant diseases--an echocardiographic pilot study].. PubMed. 84(43). 1220–3. 12 indexed citations
13.
Schefer, H. (1991). [Medical ethos of Paracelsus].. PubMed. 80(51). 1461–7.
14.
Joss, R, et al.. (1990). [Frequent errors in planning and clinical management of tumor therapy].. PubMed. 120(36). 1285–96.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026